Skip to main content

Vincent Perrone

Head of Investor Relations

UroGen Pharma Ltd. (URGN)

Equibles does not estimate personal net worth.

Get an email with a short summary when UroGen Pharma Ltd. publishes a filing, an earnings call transcript or a press release.

Get URGN alerts

About Vincent Perrone

Vincent Perrone is recorded as Head of Investor Relations at UroGen Pharma Ltd. (URGN). Vincent Perrone has spoken on 17 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on November 4, 2026. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Elizabeth Barrett (CEO and Board Member), Arie Belldegrun (Chairman and Board Member), Chris Degnan (CFO) and 7 others.

Vincent Perrone on recent calls

“Good morning, everyone, and welcome to Eurogen Pharma's third quarter, 2026 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30th, 2026.”
Head of Investor Relations, UroGen Pharma Ltd. Q3 FY2026 Earnings Call ·
“Welcome to Urgent Pharma's second quarter, 2026 Financial Results and Business Update Conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30th, 2026.”
Head of Investor Relations, UroGen Pharma Ltd. Q2 FY2026 Earnings Call ·
“Good morning everyone and welcome to your Eurogen Pharma's first quarter, 2026 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31st, 2026.”
Head of Investor Relations, UroGen Pharma Ltd. Q1 FY2026 Earnings Call ·
“Good morning, everyone, and welcome to Eurogen Pharma's full year 2025 Financial Results and Business Update conference call. Earlier this morning, we issued two press releases.”
Head of Investor Relations, UroGen Pharma Ltd. Q4 FY2025 Earnings Call ·
“Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2025 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2025.”
Head of Investor Relations, UroGen Pharma Ltd. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at UroGen Pharma Ltd.

Recent activity

Show 5 earlier activities